Revance Therapeutics, Inc. Stock price

Equities

RVNC

US7613301099

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
4.94 USD -6.88% Intraday chart for Revance Therapeutics, Inc. -21.09% -43.80%
Sales 2024 * 283M Sales 2025 * 382M Capitalization 515M
Net income 2024 * -186M Net income 2025 * -101M EV / Sales 2024 * 3.08 x
Net Debt 2024 * 355M Net Debt 2025 * 281M EV / Sales 2025 * 2.08 x
P/E ratio 2024 *
-2.39 x
P/E ratio 2025 *
-4.68 x
Employees 597
Yield 2024 *
-
Yield 2025 *
-
Free-Float 76.57%
More Fundamentals * Assessed data
Dynamic Chart
1 day-6.88%
1 week-21.09%
Current month-30.81%
1 month-11.15%
3 months-37.39%
6 months-70.42%
Current year-43.80%
More quotes
1 week
4.88
Extreme 4.88
6.37
1 month
4.88
Extreme 4.88
7.56
Current year
4.88
Extreme 4.88
9.75
1 year
4.88
Extreme 4.88
37.98
3 years
4.88
Extreme 4.88
37.98
5 years
4.88
Extreme 4.88
37.98
10 years
4.88
Extreme 4.88
42.41
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 17-09-04
President 45 18-04-01
Director of Finance/CFO 49 18-11-04
Members of the board TitleAgeSince
Chairman 68 11-02-28
Chief Executive Officer 58 17-09-04
Director/Board Member 63 19-06-03
More insiders
Date Price Change Volume
24-03-18 4.94 -6.88% 2,846,679
24-03-15 5.305 -2.30% 1,885,482
24-03-14 5.43 -9.80% 1,915,010
24-03-13 6.02 -4.22% 1,511,625
24-03-12 6.285 +0.40% 1,828,988

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings. The Company's aesthetics portfolio of expertly created products and services, including DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, the RHA Collection of dermal fillers, and OPUL, the first-of-its-kind relational commerce platform for aesthetic practices. The Company's therapeutics pipeline is focused on muscle movement disorders, including evaluating DAXXIFY in two debilitating conditions, cervical dystonia and upper limb spasticity. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient along with the other excipients. DAXXIFY a commercially approved product, is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
4.94 USD
Average target price
16.33 USD
Spread / Average Target
+230.63%
Consensus
  1. Stock
  2. Equities
  3. Stock Revance Therapeutics, Inc. - Nasdaq